Intervention Review

You have free access to this content

Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia

  1. Adib Essali1,*,
  2. Anas Rihawi2,
  3. Mohammad Altujjar3,
  4. Bishr Alhafez4,
  5. Amjad Tarboush4,
  6. Nahla Alhaj Hasan4

Editorial Group: Cochrane Schizophrenia Group

Published Online: 19 DEC 2013

Assessed as up-to-date: 7 DEC 2012

DOI: 10.1002/14651858.CD009546.pub2

How to Cite

Essali A, Rihawi A, Altujjar M, Alhafez B, Tarboush A, Alhaj Hasan N. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009546. DOI: 10.1002/14651858.CD009546.pub2.

Author Information

  1. 1

    Modern Psychiatry Hospital, Psychiatry Centre, Damascus, Syrian Arab Republic

  2. 2

    St.Elizabeth's Medical Center, Internal Medicine, Brighton, Massachusetts, USA

  3. 3

    Aleppo University, Faculty of Medicine, Aleppo, Syrian Arab Republic

  4. 4

    Damascus University, Faculty of Medicine, Damascus, Syrian Arab Republic

*Adib Essali, Psychiatry Centre, Modern Psychiatry Hospital, 27 Al Zahrawi Street, Rawda, Damascus, Syrian Arab Republic.

Publication History

  1. Publication Status: New
  2. Published Online: 19 DEC 2013



References to studies excluded from this review

  1. References to studies excluded from this review
  2. Additional references
Bai 2001 {published data only}
  • Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. Journal of Clinical Psychopharmacology 2001;21(6):608-11. [MEDLINE: 11763010]
Hui 2002 {published data only (unpublished sought but not used)}
  • Flaws B. The Chinese medical treatment of hypersalivation as an adverse reaction to anti-pyschotic medication. Blue Poppy Press 2003. [:]
  • Hui L, Xingxing P. Treatment of neuroleptic salivation by Chinese Luijunazi Wan: a clinical observation of 56 cases. China Academic Journal 2002;8:19-29.
ISRCTN47146067 2010 {published data only}
  • ISRCTN47146067. Reducing excess salivation in clozapine treatment: hyoscine for the treatment of clozapine induced nocturnal sialorrhoea, 2010.
Reinstein 1999 {published data only}
  • Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE, Mohan S. Comparative efficacy and tolerability of benzatropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clinical Drug Investigation 1999;17(2):97-102.

Additional references

  1. References to studies excluded from this review
  2. Additional references
Almeida-Filho 1997
  • Almeida-Filho N, Mari JJ, Coutinho ESF, França J, Fernandes J, Andreoli SB, et al. Brazilian multicentric study of psychiatry morbidity: methodological features and prevalence estimates [Estudo multicêntrico de morbidade psiquiátrica em áreas urbanas brasileiras (Brasilia, São Paulo, Porto Alegre)]. British Journal of Psychiatry 1997;171:524-9.
Altman 1996
  • Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
Antonello 1999
  • Antonello C. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. Journal of Psychiatry and Neuroscience 1999;24:250.
Bland 1997
  • Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des Indices d'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
Calderon 2000
  • Calderon J, Robin E, Sobota WL. Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation: a preliminary report. International Clinical Psychopharmacology 2000;15:49-52.
Carpenter 1994
Corrigan 1995
  • Corrigan F, MacDonald S, Reynolds G. Clozapine-induced hypersalivation and the alpha2 adrenoceptor. British Journal of Psychiatry 1995;167:412.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
Donner 2002
Egger 1997
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Fritz 1995
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.2 [updated March 2011]. The Cochrane Collaboration, 2011.
Hori 2006
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Leucht 2005
Leucht 2005a
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Mandel 1975
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Miyamoto 2005
  • Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005;10:79-104.
Overall 1962
  • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
Ozbilen 2009
Safferman 1991
  • Safferman A, Liberman J, Kane M, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 1991;17:247-61.
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Spivak 1997
Syed 2008
Ukai 1989
  • Ukai Y, Taniguchi T, Kimura K. Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and disopylfluorophosphate in rat submaxillary glands. Archives of International Pharmacodynamic Therapy 1989;6:148-57.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PG. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
Yaffe 2012
Zorn 1994